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MiR-222 in glioma can regulate cell cycle progression and apoptosis. However, the relationship
between miR-222 and Wnt/b-catenin signaling pathway in glioma remains unknown. Here, we
found that the Dickkopf-2 gene (DKK2) was a direct target of miR-222 by target prediction analysis
and dual luciferase reporter assay. RNA interference silencing of DKK2 proved that miR-222 overex-
pression led to constitutive activation of b-catenin through inhibition of DKK2 expression in glioma
cells. Furthermore, miR-222 siRNA signiﬁcantly inhibited tumorigenesis in vivo. Finally, Western
blot analysis showed that miR-222 could regulate the expression of b-catenin and the downstream
genes of Wnt/b-catenin signaling pathway. Taken together, our ﬁndings reveal a new regulatory
mechanism of miR-222 and suggest that miR-222 might be a potential target in glioma therapy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gliomas are themost common form of malignancy in the central
nervous system [1]. Despite therapeutic advances, the median sur-
vival time for high-grade gliomas is only 15 months [2]. Previous
studies have suggested that the formation of gliomas is related to
the rates of cell proliferation and apoptosis. Therefore, understand-
ing the main regulatory mechanism of this malignancy is the key to
developing novel and effective therapeutic strategies for gliomas.
MicroRNAs (miRNAs) are non-coding RNA molecules that regu-
late the expression of awide variety of genes through sequence-spe-
ciﬁc binding to their mRNA targets, resulting in translational
inhibition [3]. They have pivotal roles in various physiological and
pathological processes, including proliferation and apoptosis [4].
An increasing body of evidence has suggested that the aberrant
expression ofmiRNAsmay lead to the development and progression
of malignancy [5,6]. In recent years, miR-222 has been reported to
be overexpressed in human carcinomas, including thyroid papillary
tumors and glioblastoma [7,8]. Functional studies have demon-
strated that miR-222 may target multiple signaling pathway and
genes, such as p27Kip1 and PUMA, to promote the development
and progression of malignancy [9,10]. Thus, miR-222 can be classi-
ﬁed as an oncomir, and the decreased expression of miR-222 mightbe a promising strategy for cancer therapeutics. It has been demon-
strated that abnormally high activation of the Wnt/b-catenin path-
way is required for the initiation and progression of glioma[11];
however, until now, functional analysis of miR-222 and the Wnt/
b-catenin pathway has not been well-documented.
In the present study, we investigated the potential involvement
of miR-222 in glioma. We examined the expression level of miR-
222 in glioma cells, and tested its effects on cell growth, apoptosis,
and colony formation in vitro and tumorigenesis in vivo. Further-
more, we explored the underlying role of miR-222 in glioma. Final-
ly, we also analyzed the possible relationship between miR-222
and the genes downstream of the Wnt/b-catenin pathway in gli-
oma development and progression. Our study will provide a better
understanding of glioma pathogenesis.
2. Materials and methods
2.1. Reagents
Antibodies against b-actin, Bcl2, Bax, b-catenin, c-myc, DKK2,
and c-Jun were obtained from Santa Cruz Biotechnology Inc., (CA,
USA). A dual luciferase reporter assay system was obtained from
Promega Corporation (WI, USA). PGL3-promoter, PGL3-basic, and
PRL-TK vectors were also purchased from Promega. All other
chemicals were purchased from Sigma–Aldrich unless otherwise
stated.
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Glioma cell lines, including U251, U87, SHG44, A172, and a hu-
man astrocyte cell line (HA) (Cell Bank of Chinese Academy of Sci-
ence Shanghai China), were cultured in RPMI 1640 medium (Gibco
Industries, Inc., Carlsbad, CA) with 10% fetal bovine serum (Gibco
Industries, Inc). U87 and U87-miR-222-disrupted ﬂuorescent
(EGFP)-labeled cells were developed (Neuron Biotech co., Ltd,
Shanghai, China) and are referred to as Control and GR232 for
conciseness.
2.3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay
The rate of proliferationwas assessed using the colorimetricMTT
assay as describedpreviously [12]. All cellswere seeded into 96-well
culture plates (2  103 cells/well). The cells were transfected with a
miR-222mimics, control oligonucleotide, or inhibitor (antisense oli-
gonucleotide-miR-222) and grown for 4 days. One plate was devel-
oped immediately after the medium was changed, and other plates
were developed every 24 h for 4 d. Assays were initiated by adding
20 ll of MTT substrate to each well, followed by an additional 3 h
incubation. Finally, the media was removed, and 200 ll DMSO was
added to each well. Plates were read at a wavelength of 570 nm in
an Automated Microplate Reader (Multiskan Ex, Lab systems, FIN).
All experiments were biologically repeated in triplicate to conﬁrm
consistency of the results obtained.
2.4. Quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
The relative expression levels of miRNAs were determined. To-
tal RNA was isolated using TRIZOLTM reagent (Promega Corpora-
tion, WI, USA) according to the supplier’s instructions. qRT-PCR
was performed using One Step PrimeScript miRNA cDNA Synthe-
sis Kit (TaKaRa Biotechnology Ltd, Shandong, China). Real-time PCR
was performed using SYBR Green Supermix with an iCyclerther-
mal cycler (Bio-Rad Laboratories Inc, CA, USA). Primers of all genes
are described in the Supplementary data. Data were collected and
analyzed by the comparative Ct (threshold cycle) method using
GADPH as the reference gene.
2.5. Flow cytometric analysis of apoptosis
The extent of apoptosis was measured through the Annexin V-
FITC apoptosis detection kit (Invitrogen Corporation, CA, USA)
according to the manufacturer’s instructions. The cells (6  104/
well) were seeded in six-well plates in antibiotic-free media, fol-
lowed by transfection with control oligonucleotide (100 nM) or
mimics (100 nM) using Lipofectamine 2000 (Invitrogen Corpora-
tion, CA, USA). After 48 h, the cells were collected, washed with
cold PBS twice, and gently resuspended in 400 ll 1⁄binding buffer.
After adding 5 ll of Annexin V-FITC, the cells were gently vortexed
and incubated for 10 min at 4 C in the dark. Then, the tube was
incubated with 10 ll of PI for another 5 min at 4 C in the dark. Fi-
nally, the cells were analyzed using a FACScan ﬂow cytometer
(Becton Dickinson, NJ, USA). In Fig. 2C, cells in the lower right
quadrant represent early apoptosis, and those in the upper right
quadrant are representative of late apoptotic cells.
2.6. Luciferase activity assay
The 30 UTR of human DKK2 (GeneBank accession number
NM_000633) cDNA, containing the putative target sites for miR-
222, was ampliﬁed by PCR using the following primers: 50-GAT-
CGCCGTGTAATTCTAGAGTTTCATTGCCCTCT-30 (sense) and 50-CGTCGATAACTGAAACCAAAGTCAATAGCTGC-30 (anti-sense). Then, it
was inserted into the XbaI restriction site, immediately down-
stream of the luciferase gene in the pGL3-promoter-vector (Prome-
ga, Madison, WI). A mutant version with a deletion of 7 bp from a
site of perfect complementarity was also generated using the Quik-
Change II Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA).
Wild-type and mutant inserts were conﬁrmed by sequencing.
Twenty-four hours after transfection, the cells were seeded into
96-well plates (8  103 viable cells/well) and allowed to adhere
overnight. Then, 200 ng of pGL3-DKK2-30–UTR or pGL3-mut-
DKK2-30–UTR plus 80 ng pRL-SV40 (Promega Corporation, WI,
USA) was transfected alone or in combination with control oligonu-
cleotide (ﬁnal concentration of 100 nM) inhibitor (100 nM) ormim-
ics (100 nM) using Lipofectamine 2000 (Invitrogen Corporation, CA,
USA) according to the manufacturer’s protocol. Luciferase activity
was measured 48 h post-transfection using the Dual Luciferase Re-
porter Assay System (Promega Corporation, WI, USA). Fireﬂy lucif-
erase activity was normalized to renilla luciferase activity for
each transfected well. Three independent experiments were per-
formed in triplicate.
2.7. Western blot analysis
The U251 and U87 cells were seeded in six-well plates
(4  10 cells/well) in antibiotic-free media, followed by transfec-
tion withcontrol oligonucleotide (100 nM), inhibitor (100 nM), or
mimics (100 nM) using Lipofectamine 2000 (Invitrogen Corpora-
tion, CA, USA). After 48 h of culture, the cells were harvested and
homogenized with lysis buffer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 0.1% SDS, 1% Non-idet P-40, 0.5% sodium deoxycholate,
0.02% sodium azide, 100 g/ml PMSF, 1 g/ml aprotinin). Total pro-
tein extract (40 lg) was separated on 12% SDS–PAGE gels and
transferred to nitrocellulose membranes (Millipore, Bedford,
MA). After blocking with 5% non-fat dry milk in TBS, the mem-
brane was probed with primary monoclonal antibody speciﬁc
to DKK2 (1:100; Cell Signaling Technology) which was used as
an internal control for protein loading. The membrane was fur-
ther probed with horseradish peroxidase-conjugated rabbit
anti-mouse IgG (1:2000; Santa Cruz), and the protein bands
were visualized using enhanced chemiluminescence (Amersham
Pharmacia Corp., Piscataway, NJ). b-Actin was used as a loading
control.
2.8. Subcutaneous and orthotopic xenografts
For subcutaneous implantation, 5  106 Control cells (U87
cells) and GR232 cells (miR-222-disrupted U87 cells) suspended
in 100 ll PBS were injected subcutaneously into the ﬂank of
BALB/C nude mice (Cancer Institute of the Chinese Academy of
Medical Science). The mice were randomly divided into two
groups (ﬁve mice per group). Tumor growth in mice was de-
tected by the Kodak In-Vivo FX Pro system (Kodak, New York,
USA). Tumor volume of xenografts was detected every 5 days
over the course of the study with ﬂuorescence signaling. Mice
were sacriﬁced and examined 5 weeks after the subcutaneous
implantation.
All experiments were carried out under the approval of the
Administrative Panel on Laboratory Animal Care of the Xinhua
Hospital.
2.9. In vivo optical imaging
Prior to in vivo imaging, the mice were anesthetized with Phe-
nobarbital sodium. Fluorescence imaging was obtained with an
excitation wavelength of 490 nm and emission wavelength of
535 nm. Exposure times ranged from 1 to 2 min.
Fig. 1. MiR-222 overexpression promoted cell viability and colony formation, but inhibited apoptosis of glioma cells. (A) Real-time PCR was performed to quantify miR-222 in
four glioma cell lines (U251, U87, SHG44 and A172) and a human astrocyte cell line (HA). Quantiﬁcation real-time PCR reverse transcription-PCR was done on cDNA which
was generated from total RNA. All data were presented as representative of an average of three independent experiments. (B) U251 and U87 cells were transfected with a
miR-222 mimics, control oligonucleotide, or inhibitor (antisense oligonucleotide-miR-222). Up-regulated miR-222 promoted colony formation, whereas down-regulated
miR-222 restrained this activity. (C) MiR-222 mimics increased cell survival; conversely, a miR-222 inhibitor signiﬁcantly decreased survival (n = 3; means ± S.E.M. ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001 t-test). (D) Cell apoptosis was determined by ﬂow cytometry. A signiﬁcant increase in cell apoptosis was induced by the miR-222 inhibitor compared with the
negative control, while the miR-222 mimics group showed a decrease in cell apoptosis. Data are representative of 1 of 3 similar experiments.
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Statistical analyses based on the two-tailed Student’s t-test
were performed using the Statistical Package for the Social Sci-
ences software. Signiﬁcance was determined at the 95% conﬁdence
interval. All data were expressed as the mean ± standard deviation
(S.D.) from a representative experiment.3. Results
3.1. MiR-222 was overexpressed in glioma cells
The four glioma cell lines (U251, U87, SHG44 and A172) were
compared with a human astrocyte cell line (HA) (Fig. 1A). The
miR-222 expression in U251, U87, SHG44 and A172 cells was
Fig. 2. MiR-222 siRNA signiﬁcantly inhibited tumorigenesis in vivo. (A) Tumors were induced by subcutaneous implant of control cells (U87 line) and GR232 cells (miR-222-
disrupted U87 line). Tumor growth in the mice was monitored by a live imaging system detecting the ﬂuorescent (EGFP) signal (P = 0.0079, Mann–Whitney test). (B) Tumor
volume was measured every 5 days. Tumors were photographed following euthanasia. All data were presented as the mean ± S.D. and as an average of three measurements
from a representative experiment.
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cell lines, which possessed the highest levels of miR-222 expres-
sion among all tested glioma cell lines, were selected for further
studies.
3.2. MiR-222 overexpression promoted cell viability and colony
formation, but inhibited apoptosis of glioma cells
Given that miR-222 is overexpressed in glioma and that it may
act as an oncomiR, we next evaluated the oncogenic function of
miR-222 in the U251 and U87 glioma cell lines. Up-regulated
miR-222 promoted colony formation, whereas down-regulated
miR-222 restrained this activity (Fig. 1B). MTT assay showed that
transfection with miR-222 mimics increased cell survival; con-
versely, cells transfected with miR-222 inhibitors showed a signif-
icant decrease in survival (Fig. 1C). Next, we used ﬂow cytometry
to test the role of miR-222 in apoptosis. Down-regulatedmiR-222 triggered apoptosis; in contrast, up-regulated miR-222
decreased the number of cells undergoing apoptosis (Fig. 1D).
3.3. miR-222 siRNA signiﬁcantly inhibited tumorigenesis in vivo
To evaluate the effect of miR-222 in glioma, we constructed
EGFP-labeled U87 cells and miR-222-disrupted U87 cells (referred
to as control and GR232, respectively). Tumors were generated
from the control and GR232 cells by subcutaneous implantation.
Tumor volume was measured every 5 days. Tumor growth in the
mice was monitored by a live imaging system detecting the ﬂuo-
rescent (EGFP) signals. During the course of the study, miR-222-
disrupted U87 cells demonstrated signiﬁcantly inhibited tumor
growth (Fig. 2A). All data were presented as the mean ± S.D. and
as an average of three measurements from a representative exper-
iment (P = 0.0079, Mann–Whitney test). Tumor volumes were also
measured weekly. Tumors were photographed at the 5th week.
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that tumor growth was signiﬁcantly inhibited (Fig. 2B).
3.4. DKK2 is a direct target gene of miR-222
Using the algorithm Target Scan (http://www.targetscan.org),
we found that the inhibitory protein encoded by DKK2 is a target
of post-transcriptional repression by miR-222. MiR-222 has 7
nucleotides of the ‘‘seed’’ region which are complementary to the
DKK2 30-UTR (Fig. 3A), indicating that DKK2 is the potential target
of miR-222. Consequently, the down-regulation of miR-222 expres-
sion in U251 and U87 cells was concurrent with the up-regulation
of DKK2 protein expression. To ascertain whether miR-222 regu-
lates DKK2, we employed a gene overexpression approach to exam-
ine the effect of miR-222 on the DKK2 protein. The U251 and U87
cells were transfected with a miR-222 mimics or inhibitor. DKK2
protein expression, determined via Western blot, was down-regu-
lated in miR-222 mimics-transfected cells relative to the control
cells. By contrast, DKK2 protein expression was up-regulated in
miR-222 inhibitor-transfected cells (Fig. 3B). To examine whether
miR-222 directly targets DKK2, a segment of the DKK2 30-UTRFig. 3. DKK2 is a direct target gene of miR-222. (A) TargetScan predicts that miR-
222 targets the 30-UTR in the DKK2 gene. (B) DKK2 protein levels were assessed 48 h
post-transfection with miR-222 mimics (100 nM), control (100 nM), or inhibitor
(100 nM) in U251 and U87 cells. Scanning densitometry of the blots was used to
quantify the Western blotting data. (n = 3; means ± S.E.M. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 t-
test). (C) The luciferase activity in U87 cells transfected with the vector containing
the miR-222 binding sequence in the DKK2 30-UTR was inhibited by miR-222
transfection. No change in luciferase activity was observed when the cells were
transfected with a plasmid containing a DKK2 30-UTR fragment without the miR-
222 binding sites (n = 3; means ± S.E.M. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 t-test). (D) MiR-222
expression after infection with miR-222 mimics or inhibitor (n = 3; means ± S.E.M.
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 t-test).containing miR-222 binding sites was cloned into a luciferase re-
porter system. The plasmid lacking the binding sites was used as
a positive control of luciferase activity. The resulting reporter vector
was transfected into the U87 cells together with increasing concen-
trations of miR-222. Results showed that miR-222 inhibited lucifer-
ase activity in the DKK2 wild-type group. No variation in the
luciferase activity was observed when the cells were transfected
with the plasmid containing a DKK2 30-UTR fragment without the
miR-222 binding sites (Fig. 3C). In Fig 3D we show the level of
up-regulation or inhibition of miR-222 achieved upon transfection
with either the mimics or inhibitor. Hence, these results demon-
strate that miR-222 directly inhibits DKK2 expression at the post-
transcriptional level through its 30-UTR.
3.5. Relationship between miR-222 and the Wnt/b-catenin pathway
DKK2 is the inhibitor of the Wnt/b-catenin signaling pathway
[13], so we hypothesized that miR-222 might play a role relevant
to Wnt/b-catenin signaling. To test our hypothesis, we detected
the b-catenin protein levels by Western blot in miR-222 mimics-
and inhibitor-transfected cells. The b-catenin protein level was de-
creased in miR-222 inhibitor-transfected cells, contrary to the in-
creased b-catenin protein level in miR-222 mimics-transfected
cells (Fig. 4A). These data show that miR-222 functions by target-
ing the inhibitory protein DKK2, which in turn blocks theWnt/b-
catenin signaling pathway. Furthermore, we detected the genes
downstream of the Wnt/b-catenin signaling pathway, including
Bcl2, c-myc, and c-Jun. Expression of these genes was tested using
Western blot in miR-222 mimics-, control-, and inhibitor-transfec-
ted cells. Results showed that down-regulated miR-222 could re-
press the protein levels of Bcl2, c-myc, and p-c-Jun, but did not
affect c-Jun (Fig. 4B). To determine whether miR-222 functions
by targeting DKK2, we inhibited DKK2 expression by siRNA and
tested the protein levels of b-catenin, Bcl2, c-myc, and p-c-Jun.
We observed up-regulated expression of ß-catenin, Bcl2, and c-
myc; in contrast, p-c-Jun expression was down-regulated, suggest-
ing that it is independent of miR-222 inhibition (Fig. 4C). The pro-
tein expression in tumors was detected by Western blot. As shown
in Fig. 4D, DKK2 expression increased in GR232 cells in vivo, which
also conﬁrmed the in vitro results. These results indicated that
miR-222 functioned as an oncomiR by targeting DKK2.
4. Discussion
In recent years, emerging evidence has demonstrated an impor-
tant role for miRNAs in regulating human cancers [14]. At least 30%
of protein-coding genes in the human genome are regulated by
miRNAs [15]. Functional studies have directly documented the po-
tent pro- and anti-tumorigenic activity of speciﬁc miRNAs both
in vitro and in vivo [16]; therefore, miRNAs can be classiﬁed as
oncomirs or tumor-suppressive miRNAs. These miRNAs are associ-
ated with tumor cell processes like proliferation, apoptosis, angio-
genesis, migration, and metastasis [17]. Recently, it was reported
that miR-222 is overexpressed in different kinds of human cancers,
including glioblastoma [9,10]. Several studies have revealed that
miR-222 may target multiple signaling pathways, such as the
AKT pathway and EGFR signaling pathway, to promote the devel-
opment and progression of malignancy [18,19]. However, there
has been no functional analysis of miR-222 and the Wnt/b-catenin
pathway in glioma.
In the present study, we found that miR-222 was overexpressed
in glioma cells (Fig. 1A). Ectopic expression of miR-222 in vitro sig-
niﬁcantly promoted the proliferation and colony formation of gli-
oma cells, while inhibiting their apoptosis (Fig. 1B–D). To
evaluate the carcinogenesis of miR-222 in vivo, we injected miR-
222-disrupted U87 cells and normal U87 cells into nude mice.
Fig. 4. Mir-222 regulated b-catenin expression and the downstream genes of the Wnt/b-catenin signaling pathway at the protein level. U251 and U87 cells were transfected
with miR-222 mimics (100 nM), control (100 nM), or inhibitor (100 nM). The protein levels were assessed 48 h post-transfection. Scanning densitometry of the blots was also
performed to quantify the Western blotting data. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001. (A) Transfection with a Mir-222 mimics up-regulated b-catenin expression, while transfection with
inhibitor down-regulated its expression. (B) The Bcl2, c-myc, and p-c-Jun protein expression was down-regulated when transfected with miR-222 inhibitor, and the
expression was up-regulated post-transfection with miR-222 mimics. (C) Inhibition of DKK2 by siRNA clearly affected the associated protein levels. When DKK2 was inhibited
by siRNA, the expression of b-catenin, Bcl2, and c-myc was up-regulated. In contrast, p-c-Jun expression was down-regulated and appeared to be independent of miR-222. (D)
In vivo DKK2 expression was tested by Western blot analysis (P = 0.0079, Mann–Whitney test).
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signiﬁcantly less tumorigenic than the normal U87 cells in vivo
(P = 0.0079) (Fig. 2). These ﬁndings demonstrated that miR-222
can be classiﬁed as an oncomir and might be a promising targetfor cancer therapeutics. One established characteristic of
microRNAs is the ability of a single microRNA to directly target
multiple downstream genes [20]. In previous studies, it has been
reported that miR-222 can target PUMA to induce cell survival in
1748 Q. Li et al. / FEBS Letters 587 (2013) 1742–1748glioblastoma [10]. Another report demonstrated that miR-222
could target RECK to promote cancer cell proliferation in gastric
cancer [21]. These previously reported target genes may also par-
tially explain the relationship between miR-222 and the genes de-
tected in the current study. However, the mechanism of
tumorigenesis is so complex that the effect of miR-222 in glioma
development and progression remains largely unknown. In the
present study, we found by TargetScan that the 30 UTR of DKK2 is
a probable target of miR-222 (Fig. 3A). We further showed by Wes-
tern blot that miR-222 overexpression resulted in the down-regu-
lation of DKK2 at the protein level, whereas functional inhibition of
miR-222 led to DKK2 overexpression; together, these data strongly
suggest that DKK2 is regulated by miR-222 in glioma cells (Fig. 3B).
A dual luciferase reporter assay also identiﬁed DKK2 as a direct tar-
get of miR-222. Furthermore, we detected the protein levels of
DKK2 in implanted tumors by Western blot; as shown in Fig. 4D,
DKK2 expression increased in GR232 cells compared with the con-
trol. These results proved that DKK2 was a direct target of miR-222.
As DKK2 is a critical antagonist of the Wnt pathway [22], and
the wnt/b-catenin signaling pathway has been reported to be acti-
vated in glioma [23], we speculated that miR-222 might promote
tumorigenesis by regulating Wnt/b-catenin signaling via DKK2.
To elucidate the underlying mechanism, we detected the
expression levels of b-catenin and the genes downstream of the
Wnt/b-catenin signaling pathway, including Bcl2, c-myc, c-Jun
and p-c-Jun. The results showed that miR-222 overexpression
inhibited the expression of DKK2 proteins, which abrogated the
inhibitory effect of DKK2 on Wnt/b-catenin signaling. This phe-
nomenon then led to the disruption of the axin/APC/GSK3 complex,
thereby stabilizing b-catenin and permitting its subsequent activa-
tion. The activated b-catenin was then translocated into the nu-
cleus, where it in turn activated its downstream effectors and
functionally contributed to tumorigenesis [24]. In the present
study, we demonstrated for the ﬁrst time that miR-222 functions
as an oncomiR in glioma via targeting DKK2 and activating the
Wnt/b-catenin signaling pathway.
Taken together, the results suggest that miR-222 has a crucial
role in glioma progression through its target gene, DKK2; this dis-
ruption contributes to tumorigenesis via the Wnt/b-catenin signal-
ing pathway. Therefore, miR-222 could be a future therapeutic
target for the management of glioma.
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